Catalyst Biosciences Inc expected to post a loss of 66 cents a share - Earnings Preview

Gyre Therapeutics

01/11/2021 18:31

* Catalyst Biosciences Inc  CBIO.OQ   CBIO.O  is expected
to show a fall in quarterly revenue when it reports  results on
November 3 (estimated). 
* The South San Francisco, California-based company is expected
to report  a 24.4% decrease in revenue to $675 thousand from
$893 thousand a year ago, according to the mean estimate from 4
analysts, based on Refinitiv data. 
​* Refinitiv's mean analyst estimate for Catalyst Biosciences
Inc is for a loss of 66 cents per share. For the same quarter
last year, the company reported a loss of 73 cents per share.
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
* The mean earnings estimate of analysts was unchanged in the
last three months. ​
* Wall Street's median 12-month price target for Catalyst
Biosciences Inc is $16​, about 79.4% above​ its last closing
price of $3.29. ​​​
* Previous quarterly performance (using preferred earnings
measure in US dollars). ​
 QUARTER       STARMINE    REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        SMARTESTIM  IBES                 MET,    SE %
               ATE®        ESTIMATE             MISSED  
 Jun. 302021   -0.70       -0.69      -0.64     Beat    7.9
 Mar. 312021   -0.57       -0.58      -0.79     Missed  -36.8
 Dec. 312020   -0.95       -0.86      -0.86     Met     0.3​
 Sep. 302020   -0.85       -0.81      -0.73     Beat    9.5
 ​​Jun.        -0.77       -0.86      -0.96     Missed  -11.3
 302020                                                 
 Mar. 312020   -0.39       -0.36      -0.28     Beat    23.3​
 Dec. 312019   0.17        -0.31      -1.13     Missed  -258.7
 Sep. 302019   -1.05       -1.07      -1.06     Beat    0.9
 This summary was machine generated November 1 at 18:31 GMT.  All
figures in US dollars unless otherwise stated